UBX Company Profile and Key Details

UBX has shown weak momentum, losing -70.56% over the past week and -88.78% over the past quarter, though year-to-date performance is down -89.66%. Short-term trend indicators are bullishly aligned (SMA20 -69.07%, SMA50 -73.8%, SMA200 -84.33%). The stock’s 14-day RSI is 18.65 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -93.55% below its high and over 0.05% above its low.

Unity Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.95. This means the shares are trading below this model’s fair value.

Unity Biotechnology, Inc. (NASDAQ:UBX) closed at $0.20 USD, gaining $0.10 (92.77%) from the previous close of $0.10. The stock is currently mid-range between its 52-week high and low $0.10 and $3.10. With a market capitalization of about $3.44 million, Unity Biotechnology, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 761.63 thousand shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Unity Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anirvan Ghosh, the company employs approximately 16 people and listed since May 03, 2018. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.21. Next year's EPS is expected at $26.24. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 1900.0% upside. The low target suggests 1900.0% downside. The mean target is $4.00. This offers 1900.0% upside. Unity Biotechnology, Inc. earnings surprise history is a mixed track record. The quarter that ended August 05, 2025, missed forecasts by 3.33%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -29.55% in August 06, 2024.

Unity Biotechnology, Inc. has 17.21 million shares outstanding. The public float is 15.88 million shares, elevated short interest at 5.17% of float. This equals 873.20 thousand shares. The short ratio is 4.67 days. Institutional investors hold 17.52% of the float. Insiders own 1.9%. David Nathaniel E holds 624.70 thousand shares, Ghosh Anirvan has 153.45 thousand shares and Sullivan Lynne Marie has 98.90 thousand shares.

Our AI price prediction model suggests that Unity Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by August 18, 2025, within a range of $0.00 to $0.05 3-Month Outlook: Projected fall of -66.72%, reaching $0.02 by October 31, 2025, with a range of $0.00 to $0.09. 1-Year Outlook: Projected gain of 415.81%, with price at $0.31 by August 04, 2026, within a range of $0.00 to $0.33.

Unity Biotechnology, Inc. (NASDAQ:UBX) shares are down -89.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Unity Biotechnology, Inc. trading at a premium to the broader market with a P/E of -0.15. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.08, suggesting 19999.83% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-66.72% over three months), and a longer-term gain (415.81% over one year), with expected trading ranges indicating moderate volatility.

Unity Biotechnology, Inc. trades at a P/E ratio of -0.15, slightly below the S&P 500 average, with a price-to-sales ratio of 2.59 and a price-to-book ratio of -16.47 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.2, also above market averages.